Accelerate Diagnostics Inc  

(Public, NASDAQ:AXDX)   Watch this stock  
Find more results for NYSEAMEX:AXK
-0.58 (-2.84%)
Real-time:   11:53AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 19.83 - 20.66
52 week 10.29 - 29.43
Open 20.60
Vol / Avg. 85,364.00/366,009.00
Mkt cap 1.04B
P/E     -
Div/yield     -
EPS -1.11
Shares 51.22M
Beta 1.23
Inst. own 38%
Aug 8, 2016
Q2 2016 Accelerate Diagnostics Inc Earnings Call - 4:15PM EDT - Add to calendar
Aug 8, 2016
Q2 2016 Accelerate Diagnostics Inc Earnings Release - 4:00PM EDT - Add to calendar
Jun 15, 2016
Accelerate Diagnostics Inc at William Blair Growth Stock Conference
May 12, 2016
Q1 2016 Accelerate Diagnostics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -9247.85% -30951.02%
Operating margin -9307.98% -30985.71%
EBITD margin - -29766.67%
Return on average assets -45.64% -43.51%
Return on average equity -47.86% -45.72%
Employees 113 -
CDP Score - -


3950 S. Country Club Road #470 Building 3-307
TUCSON, AZ 85714-2240
United States - Map
+1-303-8638088 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company's technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types. The Company is focused on the development of a rapid diagnostic platform, the Accelerate ID/AST System (ID/AST System or Accelerate ID/AST System), intended for the diagnosis of infectious pathogens. The ID/AST System utilizes genotypic technology to identify (ID) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. The ID/AST System features walk-away automation and consists of a fixed instrument and single-use test kit.

Officers and directors

John Patience Independent Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Lawrence Mehren President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Steve Reichling Chief Financial Officer
Age: 36
Bio & Compensation  - Reuters
Ron Price Senior Vice President, Head - Commercial Operations
Bio & Compensation  - Reuters
Pete Bantock Chief Culture Officer, Head - Human Resources
Age: 49
Bio & Compensation  - Reuters
Mark C. Miller Independent Director
Age: 60
Bio & Compensation  - Reuters
Jack W. Schuler Independent Director
Age: 75
Bio & Compensation  - Reuters
Matthew W. Strobeck Ph.D. Independent Director
Age: 42
Bio & Compensation  - Reuters
Frank J M ten Brink Independent Director
Age: 58
Bio & Compensation  - Reuters